538 studies on GIP agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This real-world data strongly supports the efficacy of tirzepatide in managing metabolic syndrome, especially when combined with lifestyle interventions. The substantial weight loss and significant improvements in met…
The findings from this study are highly significant for patients managing type 2 diabetes and obesity with Tirzepatide. Knowing that injection site (upper arm, thigh, or abdomen) does not significantly impact drug abs…
This research represents a significant step towards personalized medicine in the treatment of obesity and type 2 diabetes. By understanding the genetic underpinnings of GLP-1 RA response, clinicians could potentially …
This case report is significant as it highlights a previously unreported dermatological adverse event associated with tirzepatide use. Clinicians prescribing tirzepatide should be aware of SDRIFE as a potential, albei…
This comprehensive analysis strengthens the evidence for Tirzepatide's potential as a multi-organ protective agent, extending its utility beyond metabolic control. The findings suggest that Tirzepatide could be a valu…
This Phase 3 study is critical because it directly compares two of the most promising pharmacological approaches for obesity management, potentially establishing a new standard of care. The results will provide invalu…
This study provides compelling evidence that GLP-1 medicines may offer substantial benefits beyond their primary role in weight loss and metabolic health. The observed improvements in mental health, eating disorder sy…
This study highlights the critical importance of long-term management strategies for obesity and overweight, even after successful initial weight loss with potent agents like tirzepatide. The significant weight regain…
This finding suggests that initiating Tirzepatide in patients with type 2 diabetes who are new to GLP-1 receptor agonists may offer a distinct and superior advantage in improving liver health, specifically regarding f…
This research introduces a groundbreaking approach to treating obesity and diabetes by simultaneously targeting multiple metabolic pathways. By combining GLP-1R, GIPR, and PPARα/γ/δ agonism, this strategy could offer …
This study reveals a notable disparity in the utilization of GLP1RAs among individuals with multiple sclerosis who possess cardiometabolic comorbidities that would warrant such treatment. The findings underscore the i…
This study highlights tirzepatide's profound potential as an effective add-on therapy for Type 2 Diabetes patients whose blood sugar remains poorly controlled despite existing insulin and metformin regimens. The dual …
This study is highly significant because it could establish Tirzepatide as more than just a powerful glucose-lowering agent, potentially offering a crucial benefit in addressing diabetes-related cognitive impairment. …
The successful completion of this Phase 1 safety and tolerability study is a pivotal step for LY3841136 and its potential role in obesity treatment. If LY3841136 proves to be safe and effective in combination with tir…
The findings from this study, once published, will be crucial for understanding the full therapeutic potential of incretin-based therapies beyond current GLP-1 receptor agonists. If the combined GIP and GLP-1 activati…
Given the significant public health burden of Cannabis Use Disorder and the scarcity of effective pharmacological interventions, a successful outcome from this trial could be transformative. Tirzepatide, a dual GLP-1 …
This study provides crucial evidence suggesting that Tirzepatide offers superior weight loss efficacy compared to oral semaglutide, which can significantly inform clinical decision-making for managing overweight and o…
This case report carries significant clinical implications, particularly for endocrinologists and primary care providers prescribing tirzepatide to patients with complex endocrine histories. The finding underscores th…
This systematic review provides compelling evidence that THR-β agonists may represent a more effective treatment strategy for noncirrhotic MASH compared to incretin therapies, particularly concerning histological reso…
The successful completion of SURMOUNT-CN is a crucial step towards expanding the availability of effective obesity treatments globally, specifically addressing the needs of the Chinese population. Tirzepatide, a dual …
Understanding the direct haemodynamic mechanisms of semaglutide and tirzepatide is crucial for optimizing their use in patients with cardiovascular diseases. This research could reveal novel pathways through which the…
This summary from an ICER council is crucial because it provides an independent, evidence-based assessment of the clinical and economic value of two highly effective anti-obesity medications. Such reviews are instrume…
Understanding the specific metabolic shifts induced by Semaglutide and Tirzepatide is crucial for optimizing obesity treatment strategies. If the study reveals significant, sustained improvements in energy expenditure…
This Phase 2 trial is crucial as it explores a novel combination therapy that could significantly advance the treatment landscape for obesity and Type 2 Diabetes. If successful, combining LY3841136 with Tirzepatide co…
This study addresses a critical unmet need for patients with psoriatic arthritis who also struggle with obesity, a common comorbidity that complicates disease management and often reduces the effectiveness of existing…
This research underscores a critical challenge in obesity management, suggesting that the benefits of Tirzepatide on weight loss may necessitate continuous or long-term administration to prevent relapse. The rapid wei…
Understanding the effects of GLP-1 agonist discontinuation is crucial for informing patient care and developing strategies to manage potential rebound effects and improve long-term outcomes. Many patients may need to …
Tirzepatide is already a highly effective treatment for Type II Diabetes and obesity, known for its significant glycemic control and weight loss benefits. The key implication of this study is that if Tirzepatide can d…
This study provides compelling real-world evidence that low-to-moderate doses of Tirzepatide are highly effective and well-tolerated for weight management in adults with obesity in routine clinical practice. The obser…
This review underscores the critical role of tailored dietary strategies in maximizing the therapeutic benefits of GLP-1 and dual GIP/GLP-1 receptor agonists. It suggests that integrating specific nutritional guidance…
This study provides crucial real-world evidence that Tirzepatide not only induces substantial weight loss but also favorably alters body composition by preserving lean mass and significantly improving muscle function …
This comprehensive review underscores that optimizing nutritional support is absolutely essential for maximizing the therapeutic benefits and minimizing potential risks associated with GLP-1 receptor agonist therapies…
This comprehensive systematic review solidifies the evidence for GLP-1 RAs as crucial therapeutic agents for cardiovascular protection, extending their benefits far beyond glucose control and weight management. These …
This comprehensive review provides crucial evidence for clinicians to make informed decisions when prescribing pharmacological interventions for weight management in non-diabetic adults. The significant weight loss ob…
This review is crucial for guiding future research and clinical practice in the rapidly evolving landscape of GLP-1 therapies, emphasizing a holistic approach to patient care. Understanding the psychological dimension…
This comprehensive real-world data provides crucial insights for clinicians and patients navigating treatment options for Type 2 Diabetes and obesity. The findings underscore Tirzepatide's potential for greater metabo…
Tirzepatide has already demonstrated significant efficacy, and exploring higher or alternative dosing strategies could further optimize patient outcomes by potentially enhancing glycemic control and weight loss. This …
The successful completion of this Phase 3 trial is a significant milestone, as Tirzepatide (a dual GIP and GLP-1 receptor agonist) has already demonstrated robust efficacy in adults with Type 2 Diabetes and obesity. I…
This Phase 3b study represents a significant step towards developing more holistic treatment strategies for complex conditions. If successful, combining Mirikizumab and Tirzepatide could offer a novel therapeutic opti…